Redirecting T Cells against Epstein-Barr Virus Infection and Associated Oncogenesis

The Epstein-Barr virus (EBV) is associated with lymphomas and carcinomas. For some of these, the adoptive transfer of EBV specific T cells has been therapeutically explored, with clinical success. In order to avoid naturally occurring EBV specific autologous T cell selection from every patient, the...

Full description

Saved in:
Bibliographic Details
Published in:Cells (Basel, Switzerland) Switzerland), 2020-06, Vol.9 (6), p.1400
Main Author: Münz, Christian
Format: Article
Language:English
Subjects:
adoptive T cell transfer
Adoptive transfer
Antigens
Carcinogenesis - immunology
Carcinoma
chimeric antigen receptor
Chimeric antigen receptors
Clinical Trials as Topic
Cytotoxicity
diffuse large B cell lymphoma
Epitopes - immunology
Epstein-Barr virus
Epstein-Barr Virus Infections - immunology
Gene expression
Herpesvirus 4, Human - immunology
HIV
Human immunodeficiency virus
Humans
Immune system
Infections
latent membrane protein
Lymphocytes
Lymphocytes T
Lymphoma
Mutation
nasopharyngeal carcinoma
Proteins
Review
T cell receptor
T cell receptors
T-Lymphocytes - immunology
Transplants & implants
Tumorigenesis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Epstein-Barr virus (EBV) is associated with lymphomas and carcinomas. For some of these, the adoptive transfer of EBV specific T cells has been therapeutically explored, with clinical success. In order to avoid naturally occurring EBV specific autologous T cell selection from every patient, the transgenic expression of latent and early lytic viral antigen specific T cell receptors (TCRs) to redirect T cells, to target the respective tumors, is being developed. Recent evidence suggests that not only TCRs against transforming latent EBV antigens, but also against early lytic viral gene products, might be protective for the control of EBV infection and associated oncogenesis. At the same time, these approaches might be more selective and cause less collateral damage than targeting general B cell markers with chimeric antigen receptors (CARs). Thus, EBV specific TCR transgenic T cells constitute a promising therapeutic strategy against EBV associated malignancies.
ISSN:2073-4409
2073-4409
DOI:10.3390/cells9061400